IDegAsp produces a dose-proportional glucose-lowering effect in subjects with type 1 diabetes

被引：0
|
作者：
Nosek, L. [1 ]
Heise, T. [1 ]
Klein, O. [1 ]
Coester, H. -V. [1 ]
Roepstorff, C. [2 ]
Svendsen, A. [2 ]
Haahr, H. [2 ]
机构：
[1] Profil Inst Stoffwechselforsch, Neuss, Germany
[2] Novo Nordisk AS, Soborg, Denmark
来源：
DIABETOLOGIA | 2013年 / 56卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1041
引用
收藏
页码：S418 / S419
页数：2
相关论文
共 50 条
  • [1] IDegAsp Produces Dose-Proportional Glucose-Lowering Effect in Subjects With Type 1 Diabetes
    Heise, Tim
    Nosek, Leszek
    Klein, Oliver
    Coester, Hans-Veit
    Roepstorff, Carsten
    Svendsen, Anne Louise
    Haahr, Hanne
    [J]. DIABETES, 2013, 62 : A241 - A241
  • [2] INSULIN DEGLUDEC/INSULIN ASPART (IDEGASP) PRODUCES A DOSE-PROPORTIONAL GLUCOSE-LOWERING EFFECT IN SUBJECTS WITH TYPE 1 DIABETES
    Heise, T.
    Nosek, L.
    Coester, H.
    Klein, O.
    Roepstorff, C.
    Svendsen, A. L.
    Haahr, H.
    [J]. DIABETES RESEARCH AND CLINICAL PRACTICE, 2014, 106 : S173 - S174
  • [3] Insulin degludec/insulin aspart produces a dose-proportional glucose-lowering effect in subjects with type 1 diabetes mellitus
    Heise, T.
    Nosek, L.
    Klein, O.
    Coester, H.
    Svendsen, A. L.
    Haahr, H.
    [J]. DIABETES OBESITY & METABOLISM, 2015, 17 (07): : 659 - 664
  • [4] IDegAsp Shows Distinct Prandial and Basal Glucose-Lowering Effects at Steady State in Subjects With Type 1 Diabetes
    Heise, Tim
    Nosek, Leszek
    Hastrup, Hanne
    Chenji, Suresh
    Klein, Oliver
    Haahr, Hanne
    [J]. DIABETES, 2013, 62 : A235 - A235
  • [5] IDegAsp shows distinct prandial and basal glucose-lowering effects at steady state in subjects with type 1 diabetes
    Heise, T.
    Nosek, L.
    Hastrup, H.
    Chenji, S.
    Klein, O.
    Haahr, H.
    [J]. DIABETOLOGIA, 2013, 56 : S418 - S418
  • [6] Distinct Prandial and Basal Glucose-Lowering Effects of Insulin Degludec/Insulin Aspart (IDegAsp) at Steady State in Subjects with Type 1 Diabetes Mellitus
    Tim Heise
    Leszek Nosek
    Carsten Roepstorff
    Suresh Chenji
    Oliver Klein
    Hanne Haahr
    [J]. Diabetes Therapy, 2014, 5 : 255 - 265
  • [7] Distinct Prandial and Basal Glucose-Lowering Effects of Insulin Degludec/Insulin Aspart (IDegAsp) at Steady State in Subjects with Type 1 Diabetes Mellitus
    Heise, Tim
    Nosek, Leszek
    Roepstorff, Carsten
    Chenji, Suresh
    Klein, Oliver
    Haahr, Hanne
    [J]. DIABETES THERAPY, 2014, 5 (01) : 255 - 265
  • [8] Personalized glucose-lowering effect of chiglitazar in type 2 diabetes
    Huang, Qi
    Zou, Xiantong
    Chen, Yingli
    Gao, Leili
    Cai, Xiaoling
    Zhou, Lingli
    Gao, Fei
    Zhou, Jian
    Jia, Weiping
    Ji, Linong
    [J]. ISCIENCE, 2023, 26 (11)
  • [9] Glucose-lowering medicines for type 2 diabetes
    Davoren, Peter
    [J]. AUSTRALIAN FAMILY PHYSICIAN, 2015, 44 (05) : 272 - 276
  • [10] Mechanisms of glucose-lowering effect by rosiglitazone in patients with type 2 diabetes
    Miyazaki, Y
    Matsuda, M
    Mahankali, A
    Mahankali, S
    Cusi, K
    Mandarino, L
    Defronzo, R
    [J]. DIABETES, 2001, 50 : A126 - A127
12345